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Abstract
Background: Randomized controlled trial (RCT) trial designs exist on an explanatory-pragmatic spectrum,
depending on the degree to which a study aims to address a question of efficacy or effectiveness. As
conceptualized by Schwartz and Lellouch in 1967, an explanatory approach to trial design emphasizes hypothesis
testing about the mechanisms of action of treatments under ideal conditions (efficacy), whereas a pragmatic
approach emphasizes testing effectiveness of two or more available treatments in real-world conditions. Interest in,
and the number of, pragmatic trials has grown substantially in recent years, with increased recognition by funders
and stakeholders worldwide of the need for credible evidence to inform clinical decision-making. This increase has
been accompanied by the onset of learning healthcare systems, as well as an increasing focus on patient-oriented
research. However, pragmatic trials have ethical challenges that have not yet been identified or adequately
characterized. The present study aims to explore the views of key stakeholders with respect to ethical issues raised
by the design and conduct of pragmatic trials. It is embedded within a large, four-year project that seeks to
develop guidance for the ethical design and conduct of pragmatic trials. As a first step, this study will address
important gaps in the current empirical literature with respect to identifying a comprehensive range of ethical
issues arising from the design and conduct of pragmatic trials. By opening up a broad range of topics for
consideration within our parallel ethical analysis, we will extend the current debate, which has largely emphasized
issues of consent, to the range of ethical considerations that may flow from specific design choices.
Methods: Semi-structured interviews with key stakeholders (e.g. trialists, methodologists, lay members of study
teams, bioethicists, and research ethics committee members), across multiple jurisdictions, identified based on their
known experience and/or expertise with pragmatic trials.
Discussion: We expect that the study outputs will be of interest to a wide range of knowledge users including
trialists, ethicists, research ethics committees, journal editors, regulators, healthcare policymakers, research funders
and patient groups. All publications will adhere to the Tri-Agency Open Access Policy on Publications.
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Background
Providing the best available care to patients is the back-
bone of medical practice, and a practical consequence of
the ethical principles of non-maleficence and benefi-
cence [1, 2]. Ideally, medical care should be grounded in
valid evidence of benefit, safety and cost-effectiveness
[3]. A gold standard study design for providing evidence
of effectiveness is the randomized controlled trial
(RCT) [4].
Randomized controlled trials differ in their purpose
and scope and accordingly, can have different methodo-
logical approaches. Trials that focus on elucidating a
mechanism of action or efficacy under highly-controlled
conditions are often described as explanatory or mechan-
istic trials (herein ‘explanatory RCTs’) [5–8]. Conversely,
trials whose outcomes are measuring intervention effect-
iveness in a real-world setting, and where the aim is to
provide information pertinent to a health care decision,
have been described as “practical” [6, 9] or pragmatic
(herein ‘pragmatic RCTs’) [5, 10–13]. In reality, individual
trials will lie somewhere along the spectrum from more
explanatory to more pragmatic depending on the degree
to which their aim(s) and study design are more aligned to
the study of efficacy or effectiveness.1 To help trialists
match their design decisions to the purpose of the trial,
tools such as the Pragmatic-Explanatory Continuum Indi-
catory Summary (PRECIS) and its update PRECIS-2 [14]
have been developed. PRECIS-2 proposes nine discrete
domains in which trialists can make design decisions for
the design of pragmatic RCTs. These domains are summa-
rized in Table 1. In general, the design of an RCT should
be driven by the desired purpose [6, 9].
While the notion of more explanatory and more prag-
matic attitudes within trials was first raised over 50 years
ago [5], interest in pragmatic RCTs has grown substan-
tially in recent years. Bibliometric analyses illustrate year
on year increases in the number of publications with
pragmatic trials as their topic [15, 16]. Further, a recent
Table 1 PRECIS-2 domains and descriptors
PRECIS-2 domain Description
Eligibility To what extent are the participants in the trial similar to those who would receive this intervention if it was part
of usual care? A more pragmatic trial would have criteria that ensure participants are essentially identical to those
in usual care; a more explanatory approach would have lots of exclusions (e.g. those who don’t comply, respond
to treatment, or are not at high risk for primary outcome, are children or elderly), or uses many selection tests
not used in usual care.
Recruitment How much extra effort is made to recruit participants over and above what that would be used in the usual care
setting to engage with patients? For example, a very pragmatic trial may have recruitment through usual
appointments or clinic; a very explanatory trial may have targeted invitation letters, advertising in newspapers,
radio plus incentives and other routes that would not be used in usual care.
Setting How different is the setting of the trial and the usual care setting? For example, a very pragmatic trial may use
identical settings to usual care; a very explanatory trial may include a single centre, or only specialised trial or
academic centres.
Organisation How different are the resources, provider expertise and the organisation of care delivery in the intervention
arm of the trial and those available in usual care? For example, a very pragmatic trial may use identical
organisation to usual care; a very explanatory trial may increase staff levels, give additional training, require more
than usual experience or certification and increase resources.
Flexibility (delivery) How different is the flexibility in how the intervention is delivered and the flexibility likely in usual care? For
example, a very pragmatic trial may have identical flexibility to usual care allowing healthcare professionals to
modify delivery of the intervention; a very explanatory trial may include a strict protocol, monitoring and
measures to improve compliance, with specific advice on allowed co-interventions and complications
Flexibility (adherence) How different is the flexibility in how participants must adhere to the intervention and the flexibility likely in
usual care? For example, a very pragmatic trial may involve no more than usual encouragement to adhere to
the intervention; a very explanatory approach may involve exclusion based on adherence, and measures to
improve adherence if found wanting.
Follow-up How different is the intensity of measurement and follow-up of participants in the trial and the likely follow-up
in usual care? For example, a very pragmatic trial may have no follow up than would be the case in usual care;
a very explanatory approach may have more frequent, longer visits, unscheduled visits triggered by primary
outcome event or intervening event, and more extensive data collection.
Primary outcome To what extent is the trial’s primary outcome relevant to participants? For example, a very pragmatic trial would
have an outcome is of obvious importance to participants; a very explanatory trial may use a surrogate,
physiological outcome, central adjudication or use assessment expertise that is not available in usual care, or
the outcome is measured at an earlier time than in usual care.
Primary analysis To what extent are all data included in the analysis of the primary outcome? For example, a very pragmatic trial
would use intention to treat with all available data; a very explanatory analysis may exclude ineligible
post-randomisation participants, or include only completers or those following the treatment protocol
Adapted from Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350:h2147
and https://www.precis-2.org/Help/Documentation/HowTo
Nicholls et al. BMC Medical Ethics           (2018) 19:90 Page 2 of 10
Delphi survey of 48 UK Clinical Trials Units (CTUs)
found that over 40% of CTU Directors ranked pragmatic
trials as a critical topic of interest [17]. Similarly, in a
prioritization exercise among researchers and methodol-
ogists working on trials in low and middle income coun-
tries, 84% of respondents indicated that methodological
research regarding pragmatic trials was a critical re-
search topic [18].
There are several reasons for this increased interest.
First, funding agencies such as the Patient Centered
Outcomes Research Institute (PCORI) and the Canadian
Institutes of Health Research (CIHR), among others,
have moved toward funding more pragmatic research
questions. Second, there may be a lack of evidence for
established practices – a form of “self-evident evidence
paradox” [19] – that is now coming under closer scru-
tiny. Third, there are now many new or emerging trial
designs that capitalize on methodological and statistical
innovations as well as the expansion in availability of
routinely-collected health data. This may enhance op-
portunities for pragmatism in key domains of design
such as identification and recruitment of participants,
the intensity of follow up required, and the collection of
outcome data. Examples of designs that may lend them-
selves to more pragmatic approaches include novel cluster
randomized trials (such as cluster crossovers [20, 21] and
stepped wedge trials), cohort multiple randomized design
[22], and registry-based randomized controlled trials [23].
Fourth, the cost and logistical complexity of traditional
explanatory trials has motivated funders and researchers
to identify potential ways to reduce trial costs, with prag-
matic RCTs that potentially leverage existing infrastructure
– such as health administrative data – seen as a one way to
do this [24–26]. Finally, selection of more patient-focused
trial outcomes closely aligns to increasing interest in, and
funding for, patient engagement and patient-oriented
research with national strategies such as the Canadian
Strategy for Patient Oriented Research (SPOR) [27] and the
US Patient-Centered Outcomes Research Institute (PCORI)
[28] (see Table 2 for examples).
Ethical issues in pragmatic RCTs
Pragmatic trial designs may, however, also raise new
ethical challenges. Consider the design domain of re-
cruitment: a more pragmatic RCT may attempt to re-
cruit participants by utilizing clinical staff during
routine clinical encounters. This has the potential ad-
vantages of lowering trial cost while increasing expedi-
ency, but it also has the potential to blur the line
between clinical practice and research and may raise
concerns regarding the voluntariness of patient in-
formed consent. On the other hand, a more explanatory
trial with dedicated research staff responsible for
recruiting patients is likely more costly, time consum-
ing, and may result in greater recruitment challenges,
but at the same time may provide a clearer separation
between research and clinical care, and thus, more in-
dependence in the consent process. Further, recruit-
ment undertaken by researchers may also provide more
clarity about the ethical guidelines that should be ad-
hered to in the research as opposed to a situation in
which healthcare professionals recruit participants
within routine clinical practice.
Table 2 Statements regarding pragmatic trials by funding agencies
Agency Year Definition of pragmatic trial
Canadian Institutes of Health
Research (Canada)
2016 "[innovative Clinical Trials (iCT)] methods can reduce the cost of conducting trials, reduce the amount of time
needed to answer research questions, and increase the relevance of research findings to patients, health care
providers and policy makers. Adopting these alternative designs can maximize the use of existing knowledge
and data. Some examples of iCTs include: Pragmatic trials [...];" https://www.researchnet-recherchenet.ca/rnr16/
vwOpprtntyDtls.do?prog=2471&view=search&terms=pragmatic&incArc=true&org=CIHR&fromYear=2005&toYear
=2022&type=EXACT&resultCount=25&next=1
Medical Research Council (UK) 2018 “Effectiveness Trials - Studies designed to produce research information about the
effectiveness, costs, and broader impact of health technologies for those who use,
manage and provide care in the NHS are supported by the Health Technology
Assessment (HTA) programme, funded by NIHR and managed by NETCC.”
https://mrc.ukri.org/funding/science-areas/translation/translation-and-clinical-trials/
NCCIH (US) 2017 “The projects must be pragmatic trials rather than explanatory trials. […]
The Collaboratory supports pragmatic trials. A pragmatic trial is primarily designed
to determine the effects of an intervention under the usual, real-world conditions
in which it will be applied. The approach, including study design, is kept as simple
as possible without sacrificing scientific rigor.” https://nccih.nih.gov/news/events/
telecon/pragmatic-CT-webinar-rm-16-019
PCORI (US) 2018 “[…] applicants should design trials so that they address practical comparative
questions faced by patients and clinicians—to include broader and more diverse
populations—and can be conducted in real-world clinical and diverse health-system
settings. Such trials are often referred to as “pragmatic clinical trials” because they
are intended to provide information that healthcare providers can adopt directly.”
https://www.pcori.org/sites/default/files/PCORI-PFA-2018-Cycle-1-Pragmatic-Studies.pdf
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Other examples include the domain of eligibility cri-
teria: Populations — such as pregnant women or older
patients — are routinely excluded from clinical trials [9,
14, 29–31], and are thus exposed to risks in their clin-
ical care brought about by a lack of evidence-informed
practice. These populations would benefit from improved
evidence gained by broader inclusion criteria within prag-
matic RCTs. However, their inclusion may raise concerns as
to whether additional protections need to be in place during
the trial (such as closer monitoring) and if so, when, or how
identification of potentially vulnerable populations should
take place and what appropriate responses might be.
Finally, consider the domain of data collection: prag-
matic trials commonly utilize routinely-collected data for
outcome assessment. These systems were not designed for
the purpose of capturing data for research purposes, and
questions have been raised regarding the ability of elec-
tronic health record systems to comply with requirements
set out within international research standards such as
Good Clinical Practice [32–34].
There is now an emerging body of empirical research ex-
ploring these and other ethical challenges with more prag-
matic RCTs [35–41]. Kalkman and colleagues [35], for
example, identified four key themes through interviews with
key stakeholders: that less controlled experimental condi-
tions create safety concerns regarding the patients enrolled;
that comparison between an intervention and a comparator
that constitutes suboptimal usual care may compromise
clinical equipoise; that consent processes may be modified,
but the circumstances and extent of modification are con-
tested; and that minimal interference with real-world prac-
tice drives arms to equivalence (and thus the trial may not
find a statistically or clinically significant result).
In particular, questions of consent in pragmatic trials have
been consistently raised as topics of interest and have been
studied through vignette-based research with healthcare
professionals and patients [36, 37], interviews with physi-
cians [39], deliberative engagement activities [42] and sur-
veys [41]. For example, in a study using case vignettes,
respondents preferred specific disclosure and options to ei-
ther opt-in or opt-out of research compared to a general
policy in which patients were informed broadly that a
healthcare system engages in Comparative Effectiveness Re-
search (CER) [37, 42] . Similarly, a study examining the na-
ture of CER as research or practice explored whether
physicians have a duty to participate in quality improve-
ment (QI) CER as well as whether patient consent is re-
quired for physician-targeted interventions [38]. Other
studies have explored attitudes toward consent under dif-
ferent trial scenarios. This work found that attitudes toward
consent differed not only by the type of intervention, but
also due to different design elements such as randomization
and the degree to which the trial design departed from rou-
tine clinical care [39].
Limits of the existing literature
Despite this emerging body of evidence, the current
literature has several limitations. First, few empirical
studies have been grounded in the actual experiences of
participants with the design or conduct of trials that
are more pragmatic. Further, studies have tended to
compartmentalize designs into either pragmatic or
explanatory categories. Given that trials are generally
considered to exist on a continuum between more ex-
planatory and more pragmatic trials, it makes little
sense to try and isolate ‘pragmatic’ RCTs and identify
‘their’ ethical issues. Instead, it would seem more valu-
able to identify ethical issues that may emerge from
particular trial designs, domains or dimensions of trial
pragmatism. Second, the literature is dominated by dis-
cussions set within the US healthcare context, resulting
in appeals mainly to US regulations [43–45]. Third, few
studies explicitly address governance of pragmatic trials
or the perspectives of research ethics committees who
review these trials. Fourth, studies have tended to focus
either on broad concepts such as the Learning Health-
care System [46, 47] or on a very limited number of
ethical issues. As such, debates have either tended to
lack concrete application or have been overly narrow
and deep. For example, there has been a great deal of
focus on consent [42, 46, 48–50], and insufficient atten-
tion paid to the ethical issues that arise from decisions
regarding the pragmatic or explanatory nature of indi-
vidual trial design elements.
There is, we believe, a need for constructive ethical
guidance relating to more pragmatic design choices within
RCTs. Identifying key ethical considerations and the ways
in which they are aligned with pragmatic design decisions
is an essential first step on the path to developing guid-
ance for researchers, research ethics committees and other
key stakeholders in the design and conduct of more prag-
matic RCTs. It is crucial that identification of such ethical
issues is grounded in the experiences of those directly in-
volved in the design, implementation, and evaluation of
more pragmatic RCTs.
Aim
The present study aims to explore the views of prag-
matic trial experts and key stakeholders (for example:
trialists, ethicists, methodologists, chairs of research
ethics committees, health system leaders, quality
improvement experts, and patient representatives on
research study teams) to generate a thorough under-
standing of the types of ethical issues arising in the
practice of pragmatic trials from a variety of perspec-
tives. It is the first of five planned studies embedded
within a large, four-year multi-aim project that seeks
to, ultimately, develop ethical guidance for the design
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and conduct of pragmatic trials. The protocol for the
full study is published elsewhere [51]. Within the
present study we will:
1. Explore the experiences of key stakeholders regarding
ethical issues that arise in the design and conduct of
pragmatic RCTs;
2. Identify ethical issues that arise from taking more
pragmatic (as opposed to explanatory) approaches
to design elements;
3. Elicit perspectives regarding the appropriate ethical
oversight of RCTs and how this may differ between
trials that are more pragmatic or more explanatory.
The results from this study will be used to formulate a
typology of ethical issues arising from more pragmatic
trials, to be addressed in the conceptual work within the
larger project. It will also inform the development of
data extraction items for a planned review of published
pragmatic trials, questionnaire items for a planned sur-
vey with trialists and research ethics committees, and
discussion items for focus group discussions with trial
participants.
Methods/design
The methods will involve semi-structured interviews
with key stakeholders with experience or exposure to
trials reflecting more pragmatic designs. Interviewees
will be identified using a purposive sampling strategy,
augmented through snowball sampling [52, 53].
Participants
Participants will reflect a broad range of stakeholders in
the design and conduct of clinical trials generally, and
pragmatic RCTs in particular. Specifically, we will recruit
participants within two broad groups of stakeholders:
trial experts and lay members of study teams.
Trial experts
Trial experts will include trialists, ethicists, methodolo-
gists, chairs of research ethics committees, health system
leaders, and quality improvement experts with experience
of pragmatic trials. To be considered eligible, potential in-
terviewees must be recognized experts in trials that are
more pragmatic (e.g., have been an investigator on mul-
tiple RCTs considered to be pragmatic in design, have
published papers addressing the ethical challenges in more
pragmatic RCTs, have been engaged in work regarding the
methodological development of more pragmatic ap-
proaches to RCTs or major trial designs, or have been en-
gaged in the governance or oversight of RCTs considered
to be more pragmatic in nature). Potential interviewees
will be selected across a broad range of jurisdictions and
clinical areas to reflect a range of experiences.
Lay members of study teams
Lay members of study teams (i.e., members of study
teams who have lived experience of the condition under
study or who represent the groups involved in the study
or broader community at large) will be eligible if they
have played a role in the development or implementa-
tion of a specific trial deemed to be more pragmatic in
design or have been engaged in larger study teams to en-
hance the design, conduct, or implementation of trials
that are more pragmatic in design.
The increasing inclusion of lay members in study
teams of pragmatic trials reflects the underlying premise
that trials that are more pragmatic should address
outcomes and study questions relevant to patients and
clinical practice. While previous studies of ethical issues
raised by pragmatic trials have included patients and
members of the public [37, 42], we are deliberately tar-
geting lay members of study teams who are more likely
to have been exposed to a pragmatic RCT and to have
given consideration to implications of study design
choices. Furthermore, the inclusion of lay members of
study teams will improve the saliency of the study ques-
tion and the breadth of experience upon which the par-
ticipant could draw.
Identification and recruitment
Trial experts
An initial sample of trial experts will be identified
through our extensive investigator networks, publica-
tions, and association with known centers conducting
trials that may be more pragmatic in nature. Potential
participants will be selected to ensure a breadth of ex-
perience and representation from across the identified
range of stakeholder groups. We will also ensure repre-
sentation from Canada, the US, UK, France, Australia
and Low and Middle Income Countries. We chose
these jurisdictions because they represent countries in
which the vast majority of pragmatic trials are con-
ducted, they have a rich history in methodological de-
velopmental of pragmatic trial designs, and our team
members have connections with experts and research
ethics organizations in these countries which will help
facilitate participation. Depending on the emerging
themes, we may purposively sample additional stake-
holders to ensure a diversity of opinion is sought.
Initial contact (and subsequent follow up if necessary)
with trial experts will be made via email by the study
team. The initial contact will introduce the study design
and purpose and inquire about the potential informant’s
willingness to participate. If the potential interviewee is
willing to participate, the interviewer (SN, KC) will ar-
range a time for the interview. Following confirmation
of an interview date, an overview of the interview struc-
ture will be sent to participants together with a summary
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of the PRECIS-2 domains. On the agreed date, the con-
sent form will be reviewed, and verbal consent will be
obtained to proceed with the interview.
Lay members
To begin with, lay members of study teams will be
identified via existing funded pragmatic trials or studies
addressing the design, conduct or implementation of prag-
matic trials which include lay members as part of the
study team. Examples include trials which, due to funding
requirements, require patient engagement (e.g. Ontario
SPOR Support Unit Impact Awards, Patient-Centered
Outcomes Research Institute (PCORI)) or through exist-
ing lists (e.g. PRECIS-2 list of evaluated trials: https://
www.precis-2.org/Trials), or from investigator networks.
This initial list will be supplemented through snowball
sampling.
The principal investigators for the identified studies
will be approached via email and asked to either provide
the contact information of the lay members involved in
their trial, or to forward a study invitation and consent
form on behalf of our investigator team. If the lay mem-
ber of the study team is willing to participate, the inter-
viewer (SN, KC) will arrange a time for the telephone
interview. On the agreed date, the consent form will be
reviewed, and verbal consent will be obtained to proceed
with the interview. An overview of the recruitment
process is presented in Fig. 1.
Fig. 1 Interview recruitment process
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In all cases, potential interviewees will receive a copy
of the consent form which will include an email address
and phone number that potential interviewees can use
to contact the study team if they are interested in par-
ticipating. All participants will be offered an honorarium
($100 CAD) in recognition of their participation.
Interview guide and data collection processes
Data will be collected through semi-structured inter-
views. Interviews with stakeholders will comprise three
main sections: (i) experiences with pragmatic trials,
including experiences of ethical issues; (ii) perceptions of
ethical issues relevant to pragmatic trials; and (iii) per-
spectives on oversight and regulation. Interview guides
were developed based on a review of the literature as
well as existing tools, such as PRECIS-2. Draft interview
guides were prepared by the team and pilot tested on three
pragmatic trial experts. Given the differing populations,
separate interview guides were generated for the trial ex-
perts and lay members of study teams (See Additional files 1
and 2 for interview schedules).
Interviews will be conducted by one of two members of
the team (SN/KC). Both interviewers will have experience
conducting qualitative interviews, and pilot interviews
were conducted with both team members present to en-
sure familiarity with the interview guide and consistency
of approach. The interviewers will give prompts and ask
clarifying questions in addition to the questions in the
interview protocol. Interviews will be conducted either in
person or over the telephone as required, depending on
participant availability and logistics. We anticipate the
interview sessions to take approximately 1 h.
In all cases, interviews will be audio-recorded with
consent, transcribed verbatim by a professional tran-
scription service, and imported into qualitative data ana-
lysis software (QSR International’s NVivo 10 qualitative
data analysis Software [54]) for analysis. If a participant
wishes to take part but does not wish the interview to be
audio-recorded, then written notes will be taken. During
the process of transcription, data will be de-identified
and interview transcripts will be assigned a unique par-
ticipant ID. Copies of transcribed interviews will be
made available to interviewees for additional comments.
Sample size
Qualitative approaches necessarily require small samples
due to the complex nature of the data generated and the
costs incurred by collection and analysis of the data [52,
55]. Following established qualitative research methods, our
target sample size is estimated at what will achieve satur-
ation (i.e., when new interviews cease to provide fresh infor-
mation) [52, 56–58]. While approximated, sample sizes are
based on the experience of the team [59, 60]. We anticipate
that 12–20 interviews per group of stakeholders (trial
experts and lay members of study teams) will be required
before data saturation is reached [56], and hence a total of
n = 24–40 interviews. However, as saturation of topics is
the stated end-point, additional interviews may be required
(and will be undertaken as necessary).
Analysis
The examination of the transcripts will follow a thematic
analysis approach [61, 62]. Under this methodology,
textual data contained within transcripts are coded and
labeled in an inductive manner. Using the constant com-
parison technique, data analysis occurs in parallel to the
conduct of interviews, allowing for the interview guide
to evolve and integrate emergent themes into future in-
terviews and for greater exploration of these issues.
Comparisons will be made within and across interviews
allowing for the revision, combination or separation of
codes in light of new data [63–65]. After an initial phase
of open coding, individual codes will be grouped into
overarching themes or constructs through a process of
data reduction. Analysis will be facilitated by qualitative
data analysis software (QSR International’s NVivo 10
qualitative data analysis Software [54]) to assist with the
collation and management of codes and themes.
Specifically, the analyses will consider: how pragmatic
RCTs are conceptualized and aspects identified as being
definitive components within trials that are more prag-
matic in design; ethical considerations in the design of
trials that are more pragmatic in nature; aspects of trial
design that generate ethical discussion, and; consider-
ations in the oversight or regulation of trials that are
more pragmatic in nature.
Interviews will be coded independently by two re-
searchers (SN, KC) who will then discuss between them-
selves, before presenting their analyses to the broader
team for comments and further discussion. This process
of dual coding has been suggested as a qualitative com-
parator to traditionally quantitative notions of inter-rater
reliability [66].
Discussion
This study will address important gaps in the current em-
pirical literature by identifying a comprehensive range of
ethical issues pertaining to pragmatic RCTs. Interviews will
be conducted with a broad range of stakeholders including
trialists, ethicists, methodologists, chairs of research ethics
committees, health system leaders, and lay members of
study teams. The interview guide was designed to be
grounded in the experiences of participants who are ac-
tively engaged in the design, conduct, or evaluation or
more pragmatic RCTs, which will help ensure that the
results are applicable to clinical research and practice,
as opposed to being based on hypothetical scenarios.
Furthermore, by opening up a broad range of topics for
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consideration within our parallel ethical analysis, we
will extend the current debate beyond consent to the
range of ethical considerations that may flow from spe-
cific design choices. As such, the larger program of
work which this exploratory study informs [51] prom-
ises to provide practical advice and guidance to a range
of stakeholders in the design and conduct of RCTs in-
cluding researchers, research ethics committee mem-
bers, and regulators.
A main operational issue in the present study will be
the identification and recruitment of lay members of
study teams who have had exposure to pragmatic RCTs,
and thus experience upon which to draw within the
interview. To this end we have established connections
with other stakeholder groups and identified funded
trials that are pragmatic in nature and which, due to
funding requirements, require patient engagement. This
will ensure that all lay members of study teams that are
approached will have experience of an RCT that is more
pragmatic in design.
We thus expect that the study outputs will be of
interest to a wide range of knowledge users including
trialists, ethicists, research ethics chairs, journal editors,
regulators, healthcare policymakers, research funders
and patient groups.
Endnotes
1While we acknowledge that trials that exist on a
spectrum, for simplicity we use ‘explanatory RCTs’ to
refer to those RCTs that are more explanatory and ‘prag-
matic RCTs’ to refer to those that are more pragmatic.
Additional files
Additional file 1: Trial expert interview guide. (DOC 87 kb)
Additional file 2: Lay member of study team interview guide. (DOC 74 kb)
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